Screening, risk assessment, and the approach to therapy in patients with prostate cancer (Q37801615)

23 August 2017

title

Screening, risk assessment, and the approach to therapy in patients with prostate cancer (English)

1 reference

23 August 2017

1

Stephen J. Freedland

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC:MED AND EXT_ID:20960523

6 August 2024

language of work or name

English

0 references

publication date

19 October 2010

1 reference

full work available at URL

23 August 2017

https://api.wiley.com/onlinelibrary/tdm/v1/articles/10.1002/cncr.25477

1 reference

http://onlinelibrary.wiley.com/wol1/doi/10.1002/cncr.25477/fullpdf

6 August 2024

1 reference

6 August 2024

1 reference

23 August 2017

volume

117

1 reference

23 August 2017

issue

6

1 reference

23 August 2017

page(s)

1123-1135

1 reference

23 August 2017

cites work

Cancer statistics, 2008

1 reference

Estimates of the cancer incidence and mortality in Europe in 2006.

21 January 2018

1 reference

The global state of prostate cancer: epidemiology and screening in the second millennium

21 January 2018

1 reference

Biology of prostate-specific antigen

21 January 2018

1 reference

Effect of Inflammation and Benign Prostatic Hyperplasia on Elevated Serum Prostate Specific Antigen Levels

21 January 2018

1 reference

Effect of ejaculation on serum total and free prostate-specific antigen concentrations

21 January 2018

1 reference

Prevalence of prostate cancer among men with a prostate-specific antigen level < or =4.0 ng per milliliter

21 January 2018

1 reference

Biomarkers for prostate cancer detection and progression: Beyond prostate-specific antigen.

21 January 2018

1 reference

Assessing prostate cancer risk: results from the Prostate Cancer Prevention Trial

21 January 2018

1 reference

Screening for prostate cancer--the controversy that refuses to die.

21 January 2018

1 reference

Benefits and harms of prostate-specific antigen screening for prostate cancer: an evidence update for the U.S. Preventive Services Task Force

21 January 2018

1 reference

Screening and prostate-cancer mortality in a randomized European study

21 January 2018

1 reference

Mortality results from a randomized prostate-cancer screening trial

21 January 2018

1 reference

Is prostate-specific antigen velocity selective for clinically significant prostate cancer in screening? European Randomized Study of Screening for Prostate Cancer (Rotterdam).

21 January 2018

1 reference

Prostate-specific antigen velocity for early detection of prostate cancer: result from a large, representative, population-based cohort

21 January 2018

1 reference

Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer.

21 January 2018

1 reference

A model of the natural history of screen-detected prostate cancer, and the effect of radical treatment on overall survival

21 January 2018

1 reference

Predictors of overall and cancer-free survival of patients with localized prostate cancer treated with primary androgen suppression therapy: results from the prostate cancer outcomes study

21 January 2018

1 reference

The role of primary androgen deprivation therapy in localized prostate cancer

21 January 2018

1 reference

Bicalutamide 150 mg plus standard care vs standard care alone for early prostate cancer

21 January 2018

1 reference

Clinical results of long-term follow-up of a large, active surveillance cohort with localized prostate cancer

21 January 2018

1 reference

Delayed versus immediate surgical intervention and prostate cancer outcome

21 January 2018

1 reference

Active surveillance for low-risk prostate cancer: selection of patients and predictors of progression

21 January 2018

1 reference

Active surveillance for early-stage prostate cancer: review of the current literature

21 January 2018

1 reference

High-intensity focused ultrasound for the treatment of localized prostate cancer: 5-year experience

21 January 2018

1 reference

High-intensity focused ultrasound for localized prostate cancer: initial experience with a 2-year follow-up.

21 January 2018

1 reference

Prostate cryotherapy: current status

21 January 2018

1 reference

Critical appraisal of outcomes following open radical prostatectomy

21 January 2018

1 reference

Time trends and characteristics of men choosing watchful waiting for initial treatment of localized prostate cancer: results from CaPSURE.

21 January 2018

1 reference

Prostate specific antigen recurrence after definitive therapy

21 January 2018

1 reference

A Preoperative Nomogram for Disease Recurrence Following Radical Prostatectomy for Prostate Cancer

21 January 2018

1 reference

Postoperative nomogram predicting the 10-year probability of prostate cancer recurrence after radical prostatectomy

21 January 2018

1 reference

Risk stratification for biochemical recurrence in men with positive surgical margins or extracapsular disease after radical prostatectomy: results from the SEARCH database

21 January 2018

1 reference

Preoperative nomogram predicting the 10-year probability of prostate cancer recurrence after radical prostatectomy

21 January 2018

1 reference

Pretreatment nomogram that predicts 5-year probability of metastasis following three-dimensional conformal radiation therapy for localized prostate cancer

21 January 2018

1 reference

Prostate cancer-specific mortality after radical prostatectomy for patients treated in the prostate-specific antigen era.

21 January 2018

1 reference

Impact of obesity on biochemical control after radical prostatectomy for clinically localized prostate cancer: a report by the Shared Equal Access Regional Cancer Hospital database study group

21 January 2018

1 reference

Body mass index is weakly associated with, and not a helpful predictor of, disease progression in men with clinically localized prostate carcinoma treated with radical prostatectomy

21 January 2018

1 reference

Tumour length of the largest focus predicts prostate-specific antigen-based recurrence after radical prostatectomy in clinically localized prostate cancer.

21 January 2018

1 reference

Percent tumor involvement and risk of biochemical progression after radical prostatectomy

21 January 2018

1 reference

Effect of DNA methylation on identification of aggressive prostate cancer

21 January 2018

1 reference

Natural history of progression after PSA elevation following radical prostatectomy

21 January 2018

1 reference

Risk of prostate cancer-specific mortality following biochemical recurrence after radical prostatectomy

21 January 2018

1 reference

What are the factors associated with short prostate specific antigen doubling time after radical prostatectomy? A report from the SEARCH database group.

21 January 2018

1 reference

Do nomograms predict aggressive recurrence after radical prostatectomy more accurately than biochemical recurrence alone?

21 January 2018

1 reference

Predictors of metastatic disease in men with biochemical failure following radical prostatectomy

21 January 2018

1 reference

Natural history of rising serum prostate-specific antigen in men with castrate nonmetastatic prostate cancer

21 January 2018

1 reference

Diabetes and cardiovascular disease during androgen deprivation therapy: observational study of veterans with prostate cancer

21 January 2018

1 reference

Toremifene increases bone mineral density in men receiving androgen deprivation therapy for prostate cancer: interim analysis of a multicenter phase 3 clinical study

21 January 2018

1 reference

Denosumab in men receiving androgen-deprivation therapy for prostate cancer

21 January 2018

1 reference

Phase 3, randomized, controlled trial of atrasentan in patients with nonmetastatic, hormone-refractory prostate cancer

21 January 2018

1 reference

Prognostic model for predicting survival in men with hormone-refractory metastatic prostate cancer.

21 January 2018

1 reference

Absolute prostate-specific antigen value after androgen deprivation is a strong independent predictor of survival in new metastatic prostate cancer: data from Southwest Oncology Group Trial 9346 (INT-0162).

21 January 2018

1 reference

Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer

21 January 2018

1 reference

Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer

21 January 2018

1 reference

Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer: updated survival in the TAX 327 study

21 January 2018

1 reference

Optimal timing of chemotherapy in androgen independent prostate cancer

21 January 2018

1 reference

The role of systemic cytotoxic therapy for prostate cancer

21 January 2018

1 reference

Pain predicts overall survival in men with metastatic castration-refractory prostate cancer.

21 January 2018

1 reference

Evaluation and significance of circulating epithelial cells in patients with hormone-refractory prostate cancer

21 January 2018

1 reference

Circulating tumour cells as prognostic markers in progressive, castration-resistant prostate cancer: a reanalysis of IMMC38 trial data

21 January 2018

1 reference

Long-Term Prediction of Prostate Cancer: Prostate-Specific Antigen (PSA) Velocity Is Predictive but Does Not Improve the Predictive Accuracy of a Single PSA Measurement 15 Years or More Before Cancer Diagnosis in a Large, Representative, Unscreened P

21 January 2018

1 reference

Predicting Unilateral Prostate Cancer Based on Biopsy Features: Implications for Focal Ablative Therapy—Results From the SEARCH Database

21 January 2018

1 reference

Influence of Androgen Suppression Therapy for Prostate Cancer on the Frequency and Timing of Fatal Myocardial Infarctions

21 January 2018

1 reference

A meta-analysis of the performance characteristics of the free prostate-specific antigen test

21 January 2018

1 reference

7 January 2021

EAU guidelines on prostate cancer

1 reference

7 January 2021

Clinical states in prostate cancer: toward a dynamic model of disease progression

1 reference

7 January 2021

Use of pretreatment prostate-specific antigen doubling time to predict outcome after radical prostatectomy

1 reference

7 January 2021

Prostate-specific antigen velocity and prostate cancer gleason grade and stage

1 reference

7 January 2021

Comparison of recommendations by urologists and radiation oncologists for treatment of clinically localized prostate cancer

1 reference

7 January 2021

Long-Term (15 Years) Results After Radical Prostatectomy For Clinically Localized (Stage T2c Or Lower) Prostate Cancer

1 reference

7 January 2021

The Incidence and Significance of Detectable Levels of Serum Prostate Specific Antigen After Radical Prostatectomy

1 reference

7 January 2021

Can Radical Prostatectomy Alter the Progression of Poorly Differentiated Prostate Cancer?

1 reference

7 January 2021

Prostate-specific antigen after anatomic radical retropubic prostatectomy. Patterns of recurrence and cancer control

1 reference

7 January 2021

Pretreatment nomogram for prostate-specific antigen recurrence after radical prostatectomy or external-beam radiation therapy for clinically localized prostate cancer

1 reference

7 January 2021

Pretreatment nomogram predicting ten-year biochemical outcome of three-dimensional conformal radiotherapy and intensity-modulated radiotherapy for prostate cancer

1 reference

7 January 2021

Obesity and risk of biochemical progression following radical prostatectomy at a tertiary care referral center

1 reference

7 January 2021

Stronger association between obesity and biochemical progression after radical prostatectomy among men treated in the last 10 years

1 reference

7 January 2021

Hepatic resection: the last surgical frontier for colorectal cancer

1 reference

7 January 2021

Postoperative nomogram for disease recurrence after radical prostatectomy for prostate cancer

1 reference

7 January 2021

Time to prostate specific antigen recurrence after radical prostatectomy and risk of prostate cancer specific mortality

1 reference

7 January 2021

Time to detectable metastatic disease in patients with rising prostate-specific antigen values following surgery or radiation therapy

1 reference

7 January 2021

Bone loss after initiation of androgen deprivation therapy in patients with prostate cancer

1 reference

7 January 2021

Diabetes and cardiovascular disease during androgen deprivation therapy for prostate cancer

1 reference

7 January 2021

Safety and efficacy of the specific endothelin-A receptor antagonist ZD4054 in patients with hormone-resistant prostate cancer and bone metastases who were pain free or mildly symptomatic: a double-blind, placebo-controlled, randomised, phase 2 tria

1 reference

7 January 2021

Epirubicin-based chemotherapy in metastatic breast cancer patients: role of dose-intensity and duration of treatment

1 reference

7 January 2021

Circulating Tumor Cell Number and Prognosis in Progressive Castration-Resistant Prostate Cancer

1 reference

7 January 2021

Prostate cancer screening: the continuing controversy

19

1 reference

Classification of prostatic carcinomas

6 August 2024

30

1 reference

Prostate size and risk of high-grade, advanced prostate cancer and biochemical progression after radical prostatectomy: a search database study

6 August 2024

68

1 reference

Cancer-specific mortality after radiation therapy with short-course hormonal therapy or radical prostatectomy in men with localized, intermediate-risk to high-risk prostate cancer

6 August 2024

75

1 reference

6 August 2024

Identifiers

DOI

10.1002/CNCR.25477

1 reference

23 August 2017

1 reference